Molgramostim Nebulizer Solution

About Savara

Savara is dedicated to developing and commercializing novel therapies for rare respiratory conditions with high unmet medical need. Its core asset is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), targeting the underlying immune dysfunction in aPAP. The company's strategy centers on advancing its late-stage candidate through regulatory approval while exploring its platform's potential in other orphan lung diseases. Savara operates as a lean, focused organization with significant clinical and regulatory expertise.

Therapeutic Areas